Drug Trial Radar · NCT03798054
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
878
Actual
Start
Feb 15, 2019
Primary completion
Mar 1, 2021
Study completion Mar 1, 2021
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: The co-primary objective of this study is: * To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) versus lixisenatide on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change. * To demonstrate the non-inferiority of iGlarLixi versus insulin glargine on glycemic control as assessed by HbA1c change. Secondary Objectives: * To assess the effects of iGlarLixi in comparison with insulin glargine alone and lixisenatide alone. * To assess the safety in each treatment group.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide (HOE901/AVE0010)Drug
Pharmaceutical form: solution Route of administration: subcutaneous
Insulin glargine (HOE901)Drug
Pharmaceutical form: solution Route of administration: subcutaneous
Lixisenatide (AVE0010)Drug
Pharmaceutical form: solution Route of administration: subcutaneous
MetforminDrug
Pharmaceutical form: tablet Route of administration: oral
SGLT2 inhibitorDrug
Pharmaceutical form:tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From Baseline to Week 24
Locations
79 sites in 4 countries. Site status is shown where the registry gives one.
Investigational Site Number 1560001
Beijing, China
Investigational Site Number 1560006
Beijing, China
Investigational Site Number 1560049
Beijing, China
Investigational Site Number 1560039
Cangzhou, China
Investigational Site Number 1560009
Changchun, China
Investigational Site Number 1560027
Changchun, China
Investigational Site Number 1560016
Changsha, China
Investigational Site Number 1560053
Chengdu, China
Investigational Site Number 1560056
Chengdu, China
Investigational Site Number 1560010
Chenzhou, China
Investigational Site Number 1560037
Chongqing, China
Investigational Site Number 1560050
Chongqing, China
Investigational Site Number 1560044
Dongguan, China
Investigational Site Number 1560033
Guangzhou, China
Investigational Site Number 1560028
Guangzhou, China
Investigational Site Number 1560012
Handan, China
Investigational Site Number 1560023
Hangzhou, China
Investigational Site Number 1560035
Harbin, China
Investigational Site Number 1560036
Harbin, China
Investigational Site Number 1560011
Hengshui, China
Investigational Site Number 1560024
Hohhot, China
Investigational Site Number 1560047
Hohhot, China
Investigational Site Number 3440001
Hong Kong, China
Investigational Site Number 1560026
Huanggang, China
Investigational Site Number 1560025
Huangshi, China
Investigational Site Number 1560048
Huizhou, China
Investigational Site Number 1560034
Huzhou, China
Investigational Site Number 1560005
Jinan, China
Investigational Site Number 1560052
Jinhua, China
Investigational Site Number 1560031
Jinzhou, China
Investigational Site Number 1560022
Nanjing, China
Investigational Site Number 1560014
Nanjing, China
Investigational Site Number 1560043
Nanjing, China
Investigational Site Number 1560041
Nanning, China
Investigational Site Number 1560032
Qingdao, China
Investigational Site Number 1560038
Qinhuangdao, China
Investigational Site Number 1560013
Shanghai, China
Investigational Site Number 1560007
Shanghai, China
Investigational Site Number 1560004
Shanghai, China
Investigational Site Number 1560029
Shanghai, China
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.